Ladenburg lowered the firm’s price target on Eledon Pharmaceuticals to $28 from $39 and keeps a Buy rating on the shares. The firm’s lower price target is based on dilution associated with the recent financing, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELDN:
- Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
- Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
- Eledon Pharmaceuticals price target raised to $16 from $13 at H.C. Wainwright
- Eledon Pharmaceuticals Secures $50M Through Private Placement
- Eledon Pharmaceuticals to sell 13.1M shares at $2.37 in private placement
